je.st
news
Tag: alzheimers
Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimers Disease
2013-03-13 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & AUSTIN, Texas Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Mercks Lead Investigational Medicine for Alzheimers Disease WHITEHOUSE STATION, N.J. & AUSTIN, Texas--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD). Language: English Contact HTML: Media Contacts:MerckCaroline Lappetito, 267-305-7639orLuminexMimi Torrington, 512-219-8020mtorrington@luminexcorp.comorInvestor Contacts:MerckCarol Ferguson, 908-423-4465orLuminexMatt Scalo, 512-336-3587mscalo@luminexcorp.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: LMNX Exchange: NASDAQ read more
Tags: support
enter
development
program
Innovative Assays For Alzheimer's Disease
2013-03-07 01:31:31| drugdiscoveryonline News Articles
MPI Research, the largest single-site preclinical contract research organization worldwide, is pleased to announce that it recently completed specialized training from Meso Scale Discovery (MSD) to run Aβ42 and Total Tau immunoassays on the MSD Imager platform.
Tags: disease
innovative
assays
alzheimers
Innovative Assays For Alzheimer's Disease
2013-03-07 01:31:31| drugdiscoveryonline Home Page
MPI Research, the largest single-site preclinical contract research organization worldwide, is pleased to announce that it recently completed specialized training from Meso Scale Discovery (MSD) to run Aβ42 and Total Tau immunoassays on the MSD Imager platform.
Tags: disease
innovative
assays
alzheimers
Roche Alzheimer's Push May Gain From Obama Brain-Mapping Plan
2013-02-19 12:31:52| Biotech - Topix.net
Roche AG and Eli Lilly & Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, may gain the most from a U.S. government boost in funding to fully map the human brain.
National League For Nursing To Create Alzheimer's Curricula And Resources For Nurse Educators
2013-02-13 04:37:44| dairynetwork News Articles
Between 5.6 and 8 million — nearly one in five — older Americans suffer from at least one illness affecting mental health, according to an alarming report released last year by the Institute of Medicine, "The Mental Health and Substance Use Workforce for Older Adults: In Whose Hands?"
Tags: create
resources
national
league
Sites : [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] next »